ZEMOCIMIG
UNII SZN3M97G43
Substance Identification & Data
This profile provides standardized clinical and technical data for Zemocimig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) SZN3M97G43.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2955620-21-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
SZN3M97G43
2955620-21-8
N/A
Detailed Substance Profile
Preferred Name
ZEMOCIMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13346
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Zemocimig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Zemocimig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Zemocimig
Common Names & Synonyms
H-gamma4 heavy chain anti-F9a humanized (1-447) [VH (Homo sapiens IGHV3-23*04 (87.8%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122)-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 17-G4v57-1 CH1 K84.2, 18-G4v11 CH1 Q100, CH2 Y84.3, 14-G4v12-1 CH3 K12, 12-G4v6 CH3 K88, 9-G4v78 L107, A114, 10-G4v89 CH3 R118, E120 (CH1 Q84.2>K (180), K100>Q (201) (123-220), hinge 1-12 S10>P (230) (221-232), CH2 F84.3>Y (298), L92 (311) (233-342), CH3 E12>K (358), R88>K (411), M107>L (430), N114>A (436), Q118>R (440), S120>E (442) (343-447)) (123-447)], (136-214')-disulfide with L-kappa light chain anti-F9a Homo sapiens (1'-214') [VKAPPA (Homo sapiens IGKV3D-11*02 (84.4%) -IGKJ4*01 (100%), CDRIMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (98.1%) Km3 A45.1, V101 KCv57-1 E20, E90 (C-KAPPA S20>E (131'), A45.1 (153'), T90>E (180), V101 (191')) (108'-214')]; H-gamma4 heavy chain anti-F10 humanized (1''-444'') [VH (Homo sapiens IGHV1-2*06 (74.5%) -(IGHD) -IGHJ4*01 (80.0%) Q120>E (111''), CDR-IMGT [8.8.12] (26''-33''.51''-58''.97''-108'')) (1''-119'')-Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 17-G4v57-2 CH1 E26, K84.2, 18-G4v11 CH1 Q100, CH2 Y84.3, 12-G4v6 CH3 K88, 9-G4v78 L107, A114, 10-G4v89 CH3 R118, E120, 14-G4v13 CH3 E119 (CH1 K26>E (149''), Q84.2>E (177''), K100>Q (198'') (120''-217''), hinge 1-12 S10>P (227'') (218''-229''), CH2 F84.3>Y (295''), L92 (308'') (230''-339''), CH3 R88>K (408''), M107>L (427''), N114>A (433''), Q118>R (437''), K119>E (438''), S120>E (439'') (340''-444'')) (120''-444'')], (133''-212''')-disulfide with L-lambda2 light chain anti-F10 Homo sapiens (1''-213''') [VLAMBDA (Homo sapiens IGLV3-9*01 (78.7%) -IGLJ2*01 (81.8%) L124>V (104'''), L127>V (107'''), CDR-IMGT [6.3.10] (26'''-31'''.49'''-51'''.88'''-97''')) (1'''-107''') -Homo sapiens IGLC2*01 (98.1%) LC2v57-2 K20, K90 (CLAMBDA2 T20>K (132'''), S90>K (180''')) (108'''-213''')]; dimer (228-225'': 231-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DXB11, glycoform alfa
Immunoglobulin G4 [180-lysine,201-glutamine,230-proline,298-tyrosine,358-lysine,411-lysine,430-leucine,436-alanine,440-arginine,442-glutamic acid,447-proline,de-448-glycine,de-449-lysine], bispecific, anti-(human/Macaca fascicularis blood-coagulation factor IXa) (human-Rattus norvegicus monoclonal AAE0252 γ4-chain), disulfide with human monoclonal AAE0252 κ-chain, (228→225′),(231→228′)-bis(disulfide) with immunoglobulin G4 [149-glutamic acid,177-glutamic acid,198-glutamine,227-proline,295-tyrosine,408-lysine,427-leucine,433-alanine,437-arginine,438-glutamic acid,439-glutamic acid,444-proline,de-445-glycine,de-446-lysine] anti-(human blood-coagulation factor X) (human-Mus musculus monoclonal AAE0252 γ4-chain) disulfide with human monoclonal AAE0252 λ-chain
immunoglobulin (H-gamma4_L-kappa)_( H-gamma4_L-lambda2), anti-[Homo sapiens F9a (coagulation factor F9, coagulation factor IX, hemophilia B) activated ] and anti-[Homo sapiens F10 (coagulation factor 10, coagulation factor X)], humanized and Homo sapiens monoclonal antibody, bispecific, bivalent
zemocimig [INN]
